PARP inhibitors for homologous recombination-deficient prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2018.1459563
Abstract: ABSTRACT Introduction: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched… read more here.
Keywords: prostate; prostate cancer; parp; cancer ... See more keywords
Abstract 1780: Associations between gut microbiota and PD-L1 immunotherapy/JAK1/2 inhibition in mousePten-deficient prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "Immunology"
DOI: 10.1158/1538-7445.am2021-1780
Abstract: The gut microbiome is now known to influence host immune function, malignancies, and response to therapy. We previously showed that sequencing PD-L1/JAK1/2 blockade prior to androgen deprivation therapy (ADT) could promote immune activity to potentiate… read more here.
Keywords: deficient prostate; therapy; cancer; prostate cancer ... See more keywords
Abstract 1781: Correlates of androgen deprivation and gut microbiome in mousePten-deficient prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "Immunology"
DOI: 10.1158/1538-7445.am2021-1781
Abstract: Androgen receptor (AR) signaling plays a key role in the progression of prostate cancer and androgen deprivation therapy (ADT) is one the standard of care for men with advanced prostate cancer. However, AR also exerts… read more here.
Keywords: deficient prostate; prostate cancer; androgen deprivation; cancer ... See more keywords